Research article | Open | Open Peer Review | Published:
The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells
BMC Cancervolume 18, Article number: 432 (2018)
Multiple trials have attempted to demonstrate the effective induction of cell death in TRAIL-resistant cancer cells, including using a combined treatment of recombinant TRAIL and various proteasome inhibitors. These studies have yielded limited success, as the mechanism of cell death is currently unidentified. Understanding this mechanism’s driving forces may facilitate the induction of cell death in TRAIL-resistant cancer cells.
Three kinds of recombinant soluble TRAIL proteins were treated into TRAIL-resistant cells and TRAIL-susceptible cells, with or without bortezomib, to compare their respective abilities to induce cell death. Recombinant TRAIL was treated with bortezomib to investigate whether this combination treatment could induce tumor regression in a mouse syngeneic tumor model. To understand the mechanism of combined treatment-induced cell death, cells were analyzed by flow cytometry and the effects of various cell death inhibitors on cell death rates were examined.
ILz:rhTRAIL, a recombinant human TRAIL containing isoleucine zipper hexamerization domain, showed the highest cell death inducing ability both in single treatment and in combination treatment with bortezomib. In both TRAIL-resistant and TRAIL-susceptible cells treated with the combination treatment, an increase in cell death rates was dependent upon both the dose of TRAIL and its intrinsic properties. When a syngeneic mouse tumor model was treated with the combination of ILz:rhTRAIL and bortezomib, significant tumor regression was seen as a result of the effective induction of cancer cell death. The combination treatment-induced cell death was both inhibited by TRAIL blocking antibody and caspase-dependent. However, it was not inhibited by various ER stress inhibitors and autophagy inhibitors.
The combination treatment with ILz:rhTRAIL and bortezomib was able to induce cell death in both TRAIL-susceptible and TRAIL-resistant cancer cells through the intracellular TRAIL signaling pathway. The efficiency of cell death was dependent on the properties of TRAIL under the environment provided by bortezomib. The combination treatment-induced cell death was not regulated by bortezomib-induced ER stress response or by autophagy.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was first identified in 1996 . TRAIL induces caspase-dependent apoptosis in cancer cells after binding to its corresponding receptors: DR4 or DR5 in humans and DR5 in rodents. Due to its cancer cell specific death-inducing activity, TRAIL has been regarded as a potential protector or inhibitor of tumor generation and progression [2, 3]; however, lots of tumor cell lines and primary cancer cells are resistant to TRAIL-induced apoptosis [4,5,6]. Additionally, TRAIL activates non-apoptotic signals, including NF-kB, mitogen activated kinase (MAPK), JNK, p38, Akt, and ERK [7,8,9,10,11,12,13]. TRAIL actually induces the proliferation of vascular endothelial cells and specific cancer cells, rather than inhibiting them [14,15,16]. These potential adverse effects accelerate research interest regarding the resistance mechanism of TRAIL-induced apoptosis and in the potential to combine TRAIL with an additional agent to induce apoptosis [17,18,19,20,21,22].
Research to induce cell death in TRAIL resistant cells has demonstrated some success. TRAIL induced apoptosis has been achieved through combined treatment with certain chemical agents, as well as through the genetic modification and subsequent expression of certain apoptosis related proteins [4, 7, 17, 18, 23,24,25,26,27,28,29,30,31,32,33]. Though regulating specific apoptosis-related proteins can induce cell death, this process is not applicable to all TRAIL-resistant cells because the resistance mechanisms are heterogeneous. According to published reports, several additional agents can be employed to induce apoptosis via TRAIL. Some agents regulate the balance between pro-apoptotic and anti-apoptotic proteins, while others modify membrane lipid composition to provide more opportunities for DR4 or DR5 to localize to membrane lipid rafts in specific cells. [26, 34, 35]. Many researchers have found that apoptosis-related proteins involved in the TRAIL signaling pathway do not carry any mutations. Both the expression and membrane localizations of TRAIL receptors are well regulated in almost all TRAIL resistant cells.
In this study, we hypothesized that specific intracellular conditions would be required to induce cell death in TRAIL resistant cancer cells and that these conditions could be provided by an additional agent, such as bortezomib. In addition, the effective cell death inducing ability of recombinant TRAIL would be essential. We tested various recombinant TRAIL proteins to compare cell death inducing ability; either single treatment in TRAIL-susceptible cells, or combined treatment with bortezomib in TRAIL-resistant cells. Tumor progression was inhibited with the combined treatment of bortezomib and ILz:rhTRAIL; the latter being a recombinant human TRAIL protein containing isoleucine zipper hexamerization motif for efficient multimerization. The cell death induced by the combined treatment was found to be influenced by TRAIL blocking antibody and regulated by caspases. It was not affected by ER stress or autophagy.
CT26 (80009), B16F10 (80008), MDA-MB-231 (30026), and HEK 293 (21573) cells were purchased from the Korean Cell Line Bank (KCLB, Seoul, Korea). HeLa (HC18802) and Jurkat (HC18111) cells were purchased from the Korean Collection for Type Cultures (KCTC, Daejeon, Korea). 4 T1 (CRL-2539) cells were purchased from the American Type Culture Collection (ATCC). BMK (baby mouse kidney) cells were kindly provided by Dr. J. Hiscott. The cells were cultured, according to the recommendations of KCTC, in Gibco™ Dulbecco’s Modified Eagle Medium (DMEM) or RPMI-1640 (Thermo Fisher Scientific, Pittsburg, PA, USA) supplemented with 5% fetal bovine serum (Capricorn Scientific, Ebsdorfergrund, Germany) and 1% Gibco™ penicillin-streptomycin at 37 °C in a humidified atmosphere containing 5% CO2.
Cell viability was measured by XTT assay using Cell Titer 96® Aqueous one solution reagent (Promega, Madison, WI, USA), according to the manufacture’s protocol. Cells were seeded into a 96-well plate (1 × 104 cells/well) a day before treatment with recombinant TRAIL and/or bortezomib, which was purchased by Selleck Chemicals (Houston, TX, USA). The Medium was changed to phenol-red free DMEM or RPMI with 10% of FBS and then treated with recombinant TRAIL and/or bortezomib. After an appropriate time period, substrate solution in the kit was added into the medium, and optical density was measured at 490 nm using a microplate reader (Infinite M200™; Tecan, Männedorf, Switzerland). Data are presented as the relative percentage of viable cells using the average optical density (O.D.) of the untreated control as a reference (100%) in each experiment.
Preparation of cell lysates
Cell lysates were prepared for immunoblotting analysis. Cells were harvested with ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA) and supplemented with phosphatase inhibitor cocktails-I, -II (Merck Millipore, Darmstadt, Germany). Proteins were quantified using Pierce™ BCA (bicinchoninic acid) protein assay kit (Thermo Fisher Scientific). Protein samples were loaded onto SDS-PAGE gel and transferred to Polyvinylidene difluoride (PVDF) membrane (Amersham, Buckinghamshire, England).
Immunoblotting analysis and antibodies
To examine expression levels of specific proteins, immunoblotting analysis was performed using appropriate antibodies. For immunoblotting, the membranes were immersed for 1 h into Tris-buffered saline (TBS), containing 5% skim milk (Thermo Scientific), then incubated with appropriate primary antibodies. After 3 h of incubation at room temperature or overnight at 4 °C, the membrane was washed with 0.05% TBST solution (TBS with 0.05% Tween-20) three times for 10 min each and incubated for 1 h with horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA). After extensive washing, immunoreactive proteins were detected using PowerOpti-ECL™ solution (Animal Genetics, Suweon, Korea). Intensities of reactive bands were measured and compared using Image J software (www.ImageJ.net).
Antibodies were used to neutralize TRAIL signaling and for immunoblotting analysis. Anti-TRAIL antibody (B-T24) for neutralization was purchased from Diaclone (Besançon cedex, France). For immunoblotting analysis, antibodies against caspase 3 (9662), caspase 9 (9508), Bcl-2 (2876), Bcl-XL (2764), and Mcl-1 (5453) were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-caspase-8 (ALX-804-477) antibody was purchased from Enzo Life Sciences (Farmingdale, NY, USA) and anti-β-actin antibody (MAB1501) was purchased from Millipore (Thermo Fisher Scientific). Anti-XIAP antibody (sc-55,551) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Recombinant TRAIL proteins
Recombinant human and mouse TRAIL proteins (rhTRAIL and rmTRAIL) were purchased from PeproTech (PeproTech Korea, Seoul, South Korea): rhTRAIL (310–04); rmTRAIL (315–19). ILz:rhTRAIL was constructed and purified by Dr. Kim, as described in a previous report . Briefly, hexamerization isoleucine zipper is fused to the N-terminal of recombinant human TRAIL (amino acid 114–281) resulting in ILz:rhTRAIL. The recombinant ILz:rhTRAIL protein was expressed in E. coli BL21 (DE3) and purified using a Ni-NTA His affinity column (Novagen, Carlsbad, CA, USA) according to the manufacturer’s instructions.
Cells were treated with ILz:rhTRAIL and bortezomib, with or without pre-treatment with z-VAD-fmk for 1 h. After 24 h of treatment with ILz:rhTRAIL and bortezomib, cells were harvested by trypsin treatment and stained with propidium iodide (PI) and Annexin V using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences, Thermo Fisher Scientific) for 5 min. Stained cells were analyzed by BD FACS Calibur™ analyzer and the BD CellQuest™ program (BD Biosciences, Thermo Fisher Scientific).
A syngeneic tumor model was generated to analyze whether the combined treatment of TRAIL with bortezomib could have an effect on tumor regression. Cultured CT26 cells were harvested and re-suspended with phosphate-buffered saline (PBS) following trypsin treatment. Sixty Balb/c mice, provided by Orient Bio (Sungnam, Korea), were divided into 4 groups: ‘sham’, ‘bortezomib’, ‘TRAIL’, and ‘TRAIL and bortezomib’. Cells were subcutaneously injected into the backs of all seven-week old Balb/c mice (2 × 105 cells/mouse), except for those mice in the ‘sham’ group.The size of each tumor was measured using a caliper (CD-15CPX, Mitutoyo, Japan) and tumor volume was calculated according to the equation: tumor volume = (L × W × W)/2, L = length, W = width. Ten days following the subcutaneous injection of cells, when average tumor volumes around 40 mm3 were reached, ILz:rhTRAIL (10 μg/kg) and/or bortezomib (3.8 μg/kg) were intravenously injected via tail vein. This consisted of a series of 5 injections, with a two-day interval between each injection. After these 5 injections were completed, tumor tissues were harvested, fixed with 10% formalin solution, and embedded with paraffin. Animal experiments were performed at Chosun University in accordance with the guidance of Chosun University Institutional Animal Care and Use Committee (acceptance number: CIACUC2016-A0023).
Statistical significance was determined by Student’s t-test or ANOVA single test. A two-tailed p < 0.05 was considered statistically significant.
ILz:rhTRAIL’s superiority in inducing cell death in TRAIL-susceptible cells
To identify the effect of TRAIL on cell death inducing ability, we examined the cell death rates induced by three soluble recombinant TRAIL proteins in various mouse or human cells: recombinant mouse TRAIL (rmTRAIL), recombinant human TRAIL (rhTRAIL), and isoleucine zipper hexamerization motif containing recombinant human TRAIL (ILz:rhTRAIL). The rmTRAIL and rhTRAIL used in this study either contain an extracellular domain of mouse or human TRAIL, respectively. The ILz:rhTRAIL, which contains an extracellular domain of human TRAIL and an isoleucine zipper hexamerization motif, demonstrated greater formation of multimers which in turn enhances its cell death inducing ability . According to the previous report, ILz:rhTRAIL is a pre-multimerized recombinant TRAIL and facilitates caspase activation, tBid generation, and chromatin condensation . The researchers speculated that ILz:rhTRAIL could stimulate multimerization of DR5 on the cell membrane to induce high levels of cytotoxicity. Treatment with 100 ng/ml ILz:rhTRAIL for 16 h induced cell death in 40% of HeLa cells; in contrast, treatment with either rmTRAIL or rhTRAIL failed to demonstrate any significant cell death in HeLa cells (Fig. 1a), despite their known susceptibility to TRAIL-induced apoptosis . The cell death of CT26 colon cancer cells and B16F10 melanoma cells was not induced by the three recombinant TRAILs used in this study (Fig. 1a).
To investigate whether the cells were susceptible or resistant to TRAIL-induced cell death, three human cells (Jurkat, MDA-MB 231 and HEK 293) and two mouse cells (BMK and 4 T1) were treated with three recombinant TRAIL proteins (Fig. 1b). Human leukemia cells (Jurkat cells) were susceptible to cell death in a dose-dependent manner when treated with rhTRAIL and ILz:rhTRAIL (Additional file 1: Figure S1). ILz:rhTRAIL induced cell death in human breast cancer MDA-MB-231 cells. The cell death of transformed human embryonic kidney cells (HEK 293) with sheared human adenovirus 5 DNA was induced by ILz:rhTRAIL treatment, while in contrast, cell death was only minimally seen in treatment with rhTRAIL. Furthermore, all three recombinant TRAIL proteins failed to cause any significant cell death in transformed baby mouse kidney BMK cells and mouse mammary tumor 4 T1 cells. Taken together, these results demonstrate ILz:rhTRAIL’s superiority in inducing cell death in TRAIL susceptible cells: HeLa, Jurkat, MDA-MB-231, and HEK 293.
ILz:rhTRAIL’s superiority in the combined treatment-induced cell death with bortezomib in TRAIL resistant cells
Since only four out of eight cell lines were killed by recombinant TRAIL in Fig. 1, TRAIL was combined with an additional agent to induce cell death in TRAIL-resistant cells. Proteasome inhibitors are frequently used for combined treatment with TRAIL, therefore, we used several proteasome inhibitors as adjuvants with TRAIL in CT26 and B16F10 cells [20, 38]. Bortezomib was the best additional agent to combine with TRAIL to induce cell death (data not shown). Although bortezomib induced cell death in four TRAIL resistant cell lines, cell death rates were less than 40% after 24 h, even with 100 nM of bortezomib (Additional file 2: Figure S2). Considering that the cell death rate is over 50% in bortezomib-susceptible cells treated with 10 to 50 nM of bortezomib for 24 h, these four cell lines seemed to be either completely resistant or moderately resistant to bortezomib-induced cell death .
Since the three recombinant TRAIL proteins demonstrated different cell death inducing abilities in TRAIL-susceptible cells, we decided to examine the cell death inducing ability of the combined treatment. The three different recombinant TRAIL proteins were all separately combined with bortezomib, in TRAIL resistant cells. (Fig. 2a). Individual cells were then treated with a consistent amount of recombinant TRAIL protein (100 ng/ml) and a minimal amount of bortezomib. With this approach, cell death rates were no longer dose-dependently increased as illustrated in Additional file 2: Figure S2. XTT assay demonstrated that after 24 h of treatment, over 50% of cells were killed with the combined treatment of ILz:rhTRAIL and bortezomib in three TRAIL-resistant cell types (B16F10, CT26, and BMK) (Fig. 2a). Though only about 30% of 4 T1 cells were killed with the combined treatment of ILz:rhTRAIL and bortezomib, this could still be significant considering that 4 T1 cells tended to proliferate with a single treatment of TRAIL, as seen in Fig. 1 and Additional file 3: Figure S3. Because ILz:rhTRAIL demonstrated the highest cell death inducing ability in both TRAIL-resistant cells treated with the combination therapy, and TRAIL-sensitive cells treated with ILz:rhTRAIL alone, we used ILz:rhTRAIL in further examinations of this report.
To identify the major determinant of cell death, death rates were examined following treatment with varying amounts of ILz:rhTRAIL and bortezomib (Fig. 2b, c). In TRAIL resistant B16F10 and CT26 cells, cell death rates rose dose-dependently following treatment with a fixed dose of bortezomib and increasing amounts of ILz:rhTRAIL (Fig. 2b). Cell death rates did not significantly increase when the dose of bortezomib was doubled, but the amount of ILz:rhTRAIL remained constant. These results were the same in TRAIL susceptible HEK 293 and MDA-MB 231 cells (Fig. 2c). The cell death rates observed with the combined treatment were both dependent on the dose of recombinant TRAIL protein, and regulated by its intrinsic properties.
Tumor regression induced by the combined treatment of ILz:rhTRAIL with bortezomib in a syngeneic mouse tumor model
To identify whether tumors would shrink with the combined treatment of ILz:rhTRAIL and bortezomib, a syngeneic mouse tumor model was generated. As the experimental time table in Fig. 3a shows, CT26 cells were subcutaneously injected into 7-week old Balb/c mice. On day 10, following the injection of CT26 cells, when average tumor volume reached around 40 mm3, mice were randomly grouped into four cohorts. ILz:rhTRAIL (10 μg/kg mouse) and/or bortezomib (3.8 μg/kg mouse) were administered on alternate days via tail vein, into mice belonging to the ‘ILz:rhTRAIL’, ‘bortezomib’ and ‘ILz:rhTRAIL/bortezomib’ groups. The administration interval was determined based on preliminary experiments and a previous report . Tumor volume was measured every 2-days until mice were sacrificed. The average tumor volumes recorded from 10 to 18 days after injection with CT26 cells are listed in Fig. 3b. Tumors in the ‘bortezomib’ and ‘ILz:rhTRAIL/bortezomib’ groups were reduced to 50% and 30% of their respective ‘sham’ tumor volumes prior to sacrifice. The extent of tumor regression seen in vivo, from treatment with bortezomib only or ILz:rhTRAIL/bortezomib, was reasonable considering that in in vitro studies: around 30% of CT26 cells were killed with bortezomib and 70% of CT26 cells were killed with ILz:rhTRAIL/bortezomib. Pictures, which were taken after sacrifice, of isolated tumors from each group are shown in Fig. 3c and Additional file 4: Figure S4. In each group, seven mice were sacrificed and seven tumors were isolated. In the ‘ILz:rhTRAIL/bortezomib’ group, only five tumors were isolated, as two of the seven tumors were too small to be isolated.
The combined treatment-induced cell death was mediated by caspase-dependent TRAIL signaling
Since cell death rates in the combined treatment were dependent upon recombinant TRAIL, we investigated whether TRAIL signaling could regulate this cell death. The combined treatment-induced cell death was found to be inhibited in CT26 and B16F10 cells when they were pre-treated with anti-TRAIL blocking antibody (Fig. 4a). The cell death rate was reduced with the addition of z-VAD-fmk, a pan-caspase inhibitor, and determined by XTT assay in CT26 and B16F10 cells (Fig. 4b). Annexin V-positive and propidium iodide (PI)-positive cells were shown to be increased with the combined treatment, but decreased with z-VAD-fmk pre-treatment, as demonstrated by flow cytometry analysis (Fig. 4c). Additionally, cell death was not inhibited by Necrostatin-1 in CT26 and B16F10 cells, although annexin V-negative and PI-positive cells were shown to increase (data not shown). The cell death seemed to be caused by necrotic cell death followed by apoptosis, because annexin V-negative and PI-positive cells, as well as annexin V-positive and PI-positive cells, were reduced by z-VAD-fmk (Fig. 4c).
Since the combined treatment-induced cell death was caspase-dependent apoptosis by TRAIL, profiling of apoptosis-related proteins was performed following combined treatment in CT26 and B16F10 cells (Fig. 5). Immunoblotting analysis showed that cleaved caspase 8 and caspase 3 were detected from 12 h after the combined treatment in both cell types. Bax was noted to be increased in B16F10 cells and Bax dimer was noted to be present in CT26 cells. With the combined treatment, Bcl-2, one of the anti-apoptotic proteins which counteracts Bax, was decreased in both cell types. Another counteracting anti-apoptotic protein, Bcl-xL, was decreased in combination treated CT26 cells. Expression of XIAP (X-linked inhibitor of apoptosis protein) was down-regulated from 12 h after combination treatment in both cell types.
Combined treatment-induced cell death was inhibited by neither ER stress inhibitors nor autophagy inhibitors
Bortezomib induces ER (endoplasmic reticulum) stress, and the proteins that induce this stress are known to increase TRAIL-sensitivity in some cells [41, 42]. Thus, ER stress related proteins were up-regulated by bortezomib treatment in CT26 and B16F10 cells, however the cell death induced by the combined treatment was not influenced by the addition of ER stress inhibitors in CT26 and B16F10 cells (Additional file 5: Figure S5). As the ER stress response is related to autophagy, LC-3 conversion was increased by the addition of bortezomib in B16F10 cells (Additional file 6: Figure S6 a). However, this expression regulation was not modulated by the combined treatment of ILz:rhTRAIL and bortezomib in the presence or absence of z-VAD-fmk. The combined treatment induced cell death was not regulated by Bafilomycin A1 (BfA1), an autophagy inhibitor, in CT26 and B16F10 cells (Additional file 6: Figure S6 b). The expression of downstream proteins in the mTOR pathway was modulated by bortezomib, but not by ILz:rhTRAIL (Additional file 6: Figure S6 c). The combined treatment induced cell death was not inhibited by the addition of mTOR inhibitors (rapamycin and torin-1) in either cell type (Additional file 6: Figure S6 d). Even though ER stress response proteins and autophagy related proteins were regulated by bortezomib in CT26 and B16F10 cells, these regulators should not be necessary to induce cell death with the combined treatment.
Since JNK has been reported to be both a positive and negative regulator of TRAIL-induced cell death, JNK activation was examined in CT26 and B16F10 cells, following the combined treatment [43,44,45]. Phosphorylated JNK was found to be increased in both cell types with either the combination treatment or with bortezomib alone, but not by single treatment with TRAIL. As such, SP600125 (a JNK inhibitor) was pre-treated into ILz:rhTRAIL and/or bortezomib treated cells to examine the effect of JNK on combined treatment induced cell death (Additional file 7: Figure S7). Optical densities (determined by XTT assay) in ILz:rhTRAIL and SP600125 treated CT26 and B16F10 cells were significantly reduced compared to those cells treated with ILz:rhTRAIL and bortezomib, but cell death was not observed by microscopy in ILz:rhTRAIL and SP600125 treated cells (Additional file 7: Figure S7 c). Considering the additional result that the expression and phosphorylation of JNK was not regulated by the addition of z-VAD-fmk, an inhibitor of the combined treatment-induced cell death (Additional file 7: Figure S7 a), JNK does not appear to play a regulatory role in the combined treatment-induced cell death.
In this report, we used three kinds of recombinant soluble TRAIL proteins to identify cell death inducing ability. Two of the recombinant TRAIL proteins were from PeproTech Korea, one made with extracellular domains of mouse TRAIL sequences (rmTRAIL), while the other was composed of human TRAIL sequences (rhTRAIL). The third, ILz:rhTRAIL, contained an extracellular domain of recombinant human TRAIL and an isoleucine zipper hexamerization motif. ILz:rhTRAIL demonstrated the strongest cell death inducing ability (Fig. 1). This was seen both in TRAIL susceptible cells, and in TRAIL resistant cells treated with the bortezomib (Fig. 2). Using these recombinant TRAIL proteins, we investigated TRAIL-induced apoptosis by single treatment with TRAIL and by the combined treatment with TRAIL and bortezomib in both TRAIL susceptible and TRAIL-resistant human and murine cells. Multiple cell types were chosen based on their susceptibility to TRAIL-induced apoptosis and their species origin. Some researchers have theorized that the TRAIL susceptibility of murine cells may be dependent upon the species origin of the TRAIL proteins. However, in this report, death in TRAIL-resistant murine cells was induced by combined treatment with ILz:rhTRAIL and bortezomib. To investigate the cell death-inducing ability of the combined treatment in transformed cells, HEK 293 and BMK cells were used. HEK293 cells are transformed human cells susceptible to TRAIL-induced apoptosis, whereas BMK cells are transformed cells resistant to TRAIL-induced apoptosis.
Although four TRAIL-resistant cells (CT26, B16F10, BMK and 4 T1) were shown to be resistant or moderately resistant to bortezomib, these cells demonstrated significant susceptibility to bortezomib when combined with recombinant TRAIL proteins. Though ILz:rhTRAIL contains human TRAIL sequences, when compared to the other recombinant TRAIL proteins used in this report, ILz:rhTRAIL showed the highest cell death inducing ability in all cell types regardless of TRAIL susceptibility and species specificity. In the combination treatment, rmTRAIL showed stronger cell death inducing ability than rhTRAIL in all three murine cell lines (CT26, B16F10 and 4 T1), but not in BMK cells. Although species specific binding of TRAIL could affect the combined treatment-induced cell death in some murine cells, the structural characteristics, rather than species specific sequences, of recombinant TRAIL must be a major determining factor in their susceptibility to TRAIL-induced cell death with the combined treatment.
The combination treatment demonstrates potential for use in in vivo tumor systems, as regression was seen in 70% of syngeneic mouse tumors when treated with equivalent amounts of ILz:rhTRAIL (10 μg/kg mouse) and bortezomib (3.8 μg/kg mouse): 100 ng/ml of ILz:rhTRAIL; 100 nM of bortezomib (Fig. 3). Because 25 nM of bortezomib and 50 ng/ml of ILz:rhTRAIL were enough to induce CT26 cell death in Fig. 2b, dose reduction of ILz:rhTRAIL and bortezomib could produce similar tumor regression effects in syngeneic tumor models. To induce specific cancer cell death efficiently, further studies concerning the the development of TRAIL responsiveness, the dose reduction of bortezomib, and the development of bortezomib substitutes for use in the combined treatment would be necessary.
The expression modulations, generally observed in TRAIL-induced cell death, were detected in the combined treatment, but not in single treatment with either TRAIL or bortezomib. Considering that cell death rates were dependent on the characteristics of recombinant TRAIL, and that the cell death observed was caspase-dependent apoptosis, the combined treatment-induced cell death could be regulated by recombinant TRAIL in the intracellular conditions provided by the proteasome inhibitor. This suggestion is supported by the result that the combined treatment-induced cell death was inhibited by pre-incubation of anti-TRAIL antibody for blocking in CT26 and B16F10 cells (Fig. 4a). Although bortezomib can regulate various intracellular signaling processes involved in cell death, these were not deemed to be the direct cause of cell death in the combined treatment. Bortezomib induced the ER stress response and modulated autophagy in cells, however, ER stress inhibition and regulation of autophagy were not shown to modulate the cell death induced by the combined treatment of ILz:rhTRAIL and bortezomib (Additional file 5: Figure S5 and Additional file 6: Figure S6).
In the experiment to investigate whether cell death signaling could be transmitted by JNK activation, cell death appeared to be regulated by SP600125 in ILz:rhTRAIL treated cells based on the comparison of optical densities by XTT assay (Additional file 7: Figure S7 b). Although the optical density of the XTT assay in ILz:rhTRAIL pre-treated with SP600125 was reduced to the optical density seen in the combined treated cells, microscopic observation demonstrated no cell death (Additional file 7: Figure S7 c). This may be due to inhibition of the reactivity of the XTT substrate by SP600125. The ER stress response and JNK activation have been reported as either positive or negative regulators of TRAIL-induced cell death in several cells; however, the combination treatment-induced cell death in B16F10 and CT26 cells was not regulated by the ER stress response, autophagy, or JNK activation [42, 45,46,47,48].
In the combined treatment of recombinant TRAIL with bortezomib, the ILz:rhTRAIL containing multimerization motif showed the highest ability to induce cell death, regardless of species specificity. The cell death induced by the combined treatment was shown to be regulated by the TRAIL signaling pathway under the intracellular conditions provided by bortezomib.
Activating Transcription Factor 6
CCAAT-enhancer-binding protein Homologous Protein
isoleucine zipper hexamerization motif containing recombinant human TRAIL
c-Jun N-terminal Kinase
Phosphorylated protein kinase RNA-like Endoplasmic Reticulum Kinase
Tumor necrosis factor Related Apoptosis Inducing Ligand
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687–90.
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7(1):94–100.
Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, Schutz G, Greiner EF, Kemp CJ, Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest. 2008;118(1):100–10.
Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene. 2001;20(29):3757–65.
Tomek S, Horak P, Pribill I, Haller G, Rossler M, Zielinski CC, Pils D, Krainer M. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol. 2004;94(1):107–14.
Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12(3):228–37.
Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene. 2001;20(42):6073–83.
Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery. 2005;138(2):391–7.
Braeuer SJ, Buneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res. 2006;4(10):715–28.
Kadowaki Y, Chari NS, Teo AE, Hashi A, Spurgers KB, McDonnell TJ. PI3 kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells. Apoptosis. 2011;16(6):627–35.
Liu J, Ma L, Wu N, Liu G, Zheng L, Lin X. Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway. Mar Drugs. 2014;12(9):5072–88.
Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in Cancer cells. Front Oncol. 2015;5:69.
Lee TJ, Lee JT, Park JW, Kwon TK. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun. 2006;351(4):1024–30.
Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003;107(17):2250–6.
von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 2015;27(4):561–73.
Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene. 2003;22(25):3842–52.
Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS, Pour PM. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001;7(2):407–14.
Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, Evers BM. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery. 2001;130(2):265–72.
Nozawa F, Itami A, Saruc M, Kim M, Standop J, Picha KS, Cowan KH, Pour PM. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas. 2004;29(1):45–52.
Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother. 2006;55(1):76–84.
Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer. 2006;119(4):944–54.
Fulda S, Debatin KM. Modulation of TRAIL signaling for cancer therapy. Vitam Horm. 2004;67:275–90.
Yoon JY, Cho HS, Lee JJ, Lee HJ, Jun SY, Lee JH, Song HH, Choi S, Saloura V, Park CG, et al. Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells. Mol Carcinog. 2016;55(4):387–96.
Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 2001;81(3):380–90.
Eid MA, Lewis RW, Kumar MV. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther. 2002;1(10):831–40.
Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 2002;1(5):520–7.
Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2002;50(1):46–52.
Keane MM, Rubinstein Y, Cuello M, Ettenberg SA, Banerjee P, Nau MM, Lipkowitz S. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat. 2000;64(2):211–9.
Lawrence CP, Chow SC. FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent necrosis during activation-induced cell death. FEBS Lett. 2005;579(28):6465–72.
Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005;5:54.
Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett. 2005;579(19):4069–75.
Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007;67(7):3036–42.
Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. C-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007;67(19):9425–34.
Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate. 2002;53(4):286–99.
Lim SC, Parajuli KR, Han SI. The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway. Tumour Biol. 2016;37(5):6205–16.
Han JH, Moon AR, Chang JH, Bae J, Choi JM, Lee SH, Kim TH. Potentiation of TRAIL killing activity by multimerization through isoleucine zipper hexamerization motif. BMB Rep. 2016;49(5):282–7.
Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S, Saiki I, Sakurai H. Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther. 2006;5(12):2970–6.
Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ, Liu YP. Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells. Dig Dis Sci. 2010;55(12):3361–8.
Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther. 2008;7(7):1949–60.
Bullova P, Cougnoux A, Marzouca G, Kopacek J, Pacak K. Bortezomib alone and in combination with Salinosporamid a induces apoptosis and promotes Pheochromocytoma cell death in vitro and in female nude mice. Endocrinology. 2017;158(10):3097–108.
Martin-Perez R, Niwa M, Lopez-Rivas A. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis. 2012;17(4):349–63.
Lee DH, Sung KS, Guo ZS, Kwon WT, Bartlett DL, Oh SC, Kwon YT, Lee YJ. TRAIL-induced caspase activation is a prerequisite for activation of the endoplasmic reticulum stress-induced signal transduction pathways. J Cell Biochem. 2016;117(5):1078–91.
Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem. 2003;278(23):20593–602.
Hwang MK, Ryu BJ, Kim SH. AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules. Amino Acids. 2012;43(4):1679–87.
Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S, Kruyt FA. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis. 2013;18(7):851–60.
El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology. 2011;141(2):663–73.
Wang C, Chen T, Zhang N, Yang M, Li B, Lu X, Cao X, Ling C. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J Biol Chem. 2009;284(6):3804–13.
Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress. PLoS One. 2013;8(3):e58855.
The recombinant protein ILz:rhTRAIL was purified by Ji Hye Han. BMK cells were provided by Dr. John Hiscott.
The design of this study was supported by a research fund from Chosun University (2014). The analysis and interpretation of in vitro and in vivo experiments were supported by a research fund from the National Research Foundation of Korea (NRF): NRF-2015R1D1A3A01020417. An additional research fund from NRF (Global Research Laboratory Grant: NRF-2014K1A1A2064460) supported writing the manuscript.
Availability of data and materials
The dataset shown in this report is available by request from the corresponding author, Ae Ran Moon.
Animal experiments were performed at Chosun University in accordance with the guidance of Chosun University Institutional Animal Care and Use Committee (acceptance number: CIACUC2016-A0023).
Authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure S1. Cell death was dose-dependently increased by the addition of ILz:rhTRAIL. Cells were cultured onto 96-well plates and treated with serially increasing amount of recombinant TRAIL proteins: rmT, rmTRAIL; rhT, rhTRAIL; ILz:T, ILz:rhTRAIL. Cell survival was examined by XTT assay after 24 h. (TIFF 134 kb)
Figure S2. Cell death-inducing abilities were analyzed in the 4 T1 cells after treatment with recombinant TRAIL proteins. Indicated amounts of recombinant TRAIL proteins were treated into 4 T1 cells and XTT assay was performed at 24 h: rmT, rmTRAIL; rhT, rhTRAIL; ILz:T, ILz:rhTRAIL. Statistical significance by two-tailed Student’s t-test: ***p < 0.01. (TIFF 101 kb)
Figure S3. Cell death inducing ability of bortezomib was analyzed in TRAIL-resistant cells. Four TRAIL resistant cells (B16F10, CT26, BMK, and 4 T1) were cultured onto 96-well plates with 80% to 90% confluency and treated with increasing amounts of bortezomib, labeled as “bort.” Cell death was analyzed by XTT assay 24 h after the indicated treatment. *p < 0.05 by Student’s t-test, obtained after comparison with untreated control. (TIFF 103 kb)
Figure S4. Pictures of tumors in the syngeneic mouse tumor model taken before sacrifice. Tumor volumes were measured and pictures were taken 18 days after the CT26 injection. (TIFF 2911 kb)
Figure S5. Combined treatment-induced cell death was not inhibited by the addition of ER stress inhibitors. Cultured B16F10 (A) and CT26 cells (B) were treated with 100 nM of bortezomib for the indicated period and harvested using RIPA buffer. Immunoblotting analysis was performed using appropriate antibodies against ER stress responsive proteins: ATF6, activating transcription factor 6; CHOP, CCAAT-enhancer-binding protein homologous protein; p-PERK, phosphorylated protein kinase RNA-like Endoplasmic reticulum kinase. (C) B16F10 cells, pre-treated with various ER stress inhibitors for 3 h, were treated with ILz:rhTRAIL (100 ng/ml) and bortezomib (100 nM): ILz:T/B, combined treatment of ILz:rhTRAIL and bortezomib; 4μ8C (10 nM), IRE1 inhibitor; GSK (30 nM), PERK inhibitor (GSK2606414); sal (30 μM), selective inhibitor of eIF2α phosphorylation (salubrinal). After 36 h, live cells were stained with crystal violet. (TIFF 523 kb)
Figure S6. Combined treatment-induced cell death was not inhibited by the addition of autophagy inhibitors. (A, B) Cultured B16F10 cells were treated with ILz:rhTRAIL (100 ng/ml) and bortezomib (100 nM) with or without z-VAD-fmk, pan-caspase inhibitor: ILz:T, ILz:rhTRAIL; B, bortezomib; Z, z-VAD-fmk. After the indicated period, cells were harvested and cell lysates were prepared for immunoblotting analysis using appropriate antibodies: LC-3, microtubule-associated protein 1A/1B-light chain 3; Atg5, autophagy protein 5; p-S6, phosphorylated ribosome protein S6; p-S6K, phosphorylated ribosomal protein S6 kinase. (C) B16F10 and CT26 cells were cultured onto a 96-well plate and treated with ILz:rhTRAIL (100 ng/ml) and/or bortezomib (100 nM) following pre-treatment with Bafilomycin A1 (BfA1) for 3 h. Cell death was analyzed by XTT assay 24 h after the ILz:rhTRAIL and/or bortezomib treatment. (D) After pre-treatment with rapamycin (100 nM) or torin-1 (1 μM) for 3 h, ILz:rhTRAIL (100 ng/ml) and bortezomib (100 nM) were treated into cells: rapa, rapamycin. Cell death was analyzed by XTT assay 24 h after the ILz:rhTRAIL and bortezomib treatment. *p < 0.05 by Student’s t-test. (TIFF 236 kb)
Figure S7. Cell death was not regulated by the addition of SP600125 in ILz:rhTRAIL treated cells. (A) CT26 and B16F10 cell lysates were prepared following the ILz:rhTRAIL and/or bortezomib treatment. Immunoblotting analysis was performed using anti-JNK or anti-phosphorylated JNK antibodies: ILz:T, ILz:rhTRAIL; B, bortezomib; Z, z-VAD-fmk. (B) CT26 and B16F10 cells were cultured onto a 96 well-plate and treated with ILz:rhTRAIL and/or bortezomib with or without SP600125 pre-treatment (1μg/ml) for 3 h: T, ILz:rhTRAIL (100 ng/ml); B, bortezomib (100 nM); SP, SP600125. After 24 h of ILz:rhTRAIL and/or bortezomib treatment, XTT assay was performed. *p < 0.05 by Student’s t-test. (C) The morphology of ILz:rhTRAIL and/or bortezomib treated B16F10 cells was observed microscopically after 24 h: ILz:T, ILz:rhTRAIL; B, bortezomib; SP, SP600125. (TIFF 464 kb)